<DOC>
	<DOCNO>NCT02495012</DOCNO>
	<brief_summary>A Phase IIb clinical trial investigate safety efficacy antiplatelet thrombolysin injection patient ST Segment Elevation Myocardial Infarction ( STEMI ) receive PCI therapy , order provide evidence Phase III design .</brief_summary>
	<brief_title>Anfibatide Treatment STEMI Patients</brief_title>
	<detailed_description>Anfibatide snake venom , investigate human many year phase 1 &amp; 2a study . A Phase IIb clinical trial investigate safety efficacy antiplatelet thrombolysin injection patient ST Segment Elevation Myocardial Infarction ( STEMI ) receive PCI therapy , order provide evidence Phase III design .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Aged 1875 year ; 2 . Fulfill standard direct PCI : ST Segment Elevation Myocardial Infarction occur &lt; 12 hour ( ST Segment Elevation New Left Bundle Branch Block ( LBBB ) , combine myocardial ischemia chest pain medical history dynamic change cardiac marker ( troponin and/or CKMB ) ; 3 . Patients receive PCI suitable angioplasty stent placement ; 4 . Patients , family guardian give sign informed consent form . 1 . Patients weight &lt; 50kg ; 2 . Patients severe hepatic renal dysfunction , alanine aminotransferase ( ALT ) exceed 3 time normal maximum reference level , creatinine clearance level &lt; 30ml/min serum creatinine ≥ 200μmol/L ≥2.5mg/dl ; 3 . Patients severe hemodynamic instability ; 4 . Patients receive 2 time PCI treatment ; 5 . Patients heart function decompensatory phase ( Killip grade 34 ) cardiac shock ; 6 . Patients untreated hypertension ( SBP &gt; 180mmHg DBP &gt; 110mmHg ) hypotension shock ( SBP &lt; 90mmHg ) ; 7 . Patients receive GPIIb/IIIa receptor antagonist and/or thrombolytic therapy randomization ; 1 . Used eptifibatide tirofiban past 12 hour randomization ; 2 . Used abxicimab past 7 day randomization ; 3 . Have receive thrombolytic therapy randomization ; 8 . Patients need longterm treatment clopidogrel ; 9 . Patients receive enoxaparin sodium injection surgery ; 10 . Patients hemorrhage risk : 1 . Suffered ischemic stroke transient ischemic attack ( TIA ) past 12 month ; 2 . Suffered hemorrhage stroke , lifelong neuronal dysfunction ; 3 . Suffered tumor , arteriovenous malformation brain aneurysm ; 4 . Suffered traumatic brain injury past 3 month , receive major surgery ; 5 . Received percutaneous coronary intervention ( PCI ) past 6 month ; 6 . Have receive coronary artery bypass graft therapy ( CABG ) ; 7 . Receiving longterm oral anticoagulant therapy ; 8 . Suffered active peptic ulcer , urinary reproductive tract hemorrhage , active hemorrhage . 11 . Patients coagulation disorder : 1 . Known international normalized ratio &gt; 2* ; 2 . Patients coagulation abnormality hemorrhagic tendency ( include inherit hemorrhagic disease , e.g . Von Willebrand disease hemophilia ; acquire hemorrhagic disease ; clinically identify hemorrhagic disease unsolved rationale ) ; 3 . Hematology test show platelet count &lt; 100x109mm3/L , hemoglobin &lt; 100g/L ; 4 . Recorded clopidogrelrelated thrombocytopenia agranulocytosis ; 12 . Life expectancy &lt; 1 year ; 13 . Patients implemented pacemaker , contraindicate MRI examination ; 14 . Patients allergic constitution allergic component aspirin , clopidogrel , creatinine , antiplatelet thrombolysin investigational product ; 15 . Women pregnant lactation period , woman childbearing age take efficient contraception measure ; 16 . Patients participate participate clinical trial ; 17 . Patients participate clinical trial antiplatelet thrombolysin related trial ; 18 . Patients suitable participate clinical trial accord investigator 's judgment , include unable unwilling follow protocol ; 19 . Patients participate clinical trial past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>STEMI</keyword>
</DOC>